SCHEMBL21966580

SCHEMBL21966580

O=C(O)C1C2CC(Sc3ccccc3[N+](=O)[O-])C(Cl)C2c2cccc3c2N1CC1CCCC31

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 2/20 0.74
MCL1 Q07820 4/20 0.65
BCL2 P10415 1/20 0.65
BID P55957 1/20 0.65
MEN1 O00255 9/20 0.55
KMT2A Q03164 9/20 0.55
POLB P06746 6/20 0.55
L3MBTL1 Q9Y468 5/20 0.55
GAA P10253 4/20 0.55
TDP1 Q9NUW8 4/20 0.55
HPGD P15428 3/20 0.55
BLM P54132 2/20 0.55
ALOX12 P18054 2/20 0.55
THRB P10828 2/20 0.55
USP2 O75604 1/20 0.55
GRK2 P25098 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
PTPN5 P54829 6/20 0.51
MAPT P10636 8/20 0.49
PTPN7 P35236 4/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16706086 0.71 MEN1 (1.00) FABP4MCL1BCL2BIDMEN1
SCHEMBL21968899 0.69 FABP4 (1.00) FABP4MCL1BCL2BIDMEN1
SCHEMBL8328341 0.60 MAPT (0.56) FABP4MCL1MEN1KMT2APOLB
SCHEMBL8028472 0.60 MAPT (0.51) FABP4MCL1MEN1KMT2APOLB
SCHEMBL9469352 0.59 MAPT (0.47) FABP4MEN1KMT2ATDP1SMN1; SMN2
SCHEMBL875286 0.58 MAPT (0.57) MEN1KMT2AL3MBTL1GAATDP1
SCHEMBL13554691 0.56 MAPT (0.71) MEN1KMT2APOLBSMN1; SMN2MAPT
SCHEMBL5262117 0.56 MAPT (0.62) MEN1KMT2AGAAHPGDSMN1; SMN2
SCHEMBL6759187 0.55 MAPT (0.65) MEN1KMT2AGAAHPGDSMN1; SMN2
SCHEMBL31315669 0.55 MAPT (0.65) MEN1KMT2AGAAHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11229624-B2 FABP4 as a therapeutic target in skin diseases TICURE LTD. (IL) 2022-01-25 US disclosed
US-20200138779-A1 FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES TICURE LTD. (IL) 2020-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11229624-B2 FABP4 as a therapeutic target in skin diseases FABP4, FABP2, FABP1 FABP4 1/4885MCL1 563/4885BCL2 883/4885
US-20200138779-A1 FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES FABP4, FABP2, FABP1 FABP4 1/4885MCL1 563/4885BCL2 883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.